A cluster-randomized, placebo-controlled trial to evaluate the efficacy of a spatial repellent (Mosquito Shield™) against Aedes-borne virus infection among children ≥ 4–16 years of age in the Gampaha District, Sri Lanka: study protocol (the AEGIS program)

Table 5 Case classifications for longitudinal samples

Case classification	Description
LTFU	Participants who move from the study area or choose to stop participation in febrile surveillance.
Not DENV infected	No change in PRNT or MNT results between longitudinal bleeds
Inapparent infection	Change in PRNT or MNT results consistent with a seroconversion between longitudinal bleeds without indication of febrile illness coincident with a laboratory-diagnosed DENV infection. Seroconversion meaning Baseline=Negative or Monotypic, 12- and 24-month sample=positive for dengue antibody or positive for antibody against a new DENV serotype in the case of monotypics.
Symptomatic infection	Clinical case identified in passive febrile surveillance with laboratory confirmation of DENV infections (see Fig. 3), which may include laboratory-confirmed seroconversion from acute and convalescent blood samples.

ISSN: 1745-6215